Stock Track | Mesoblast Soars 16.93% as Key Drug Ryoncil Secures US Medicare Billing Approval

Stock Track

Oct 03, 2025

Mesoblast Ltd (MSB.AU) shares skyrocketed 16.93% in Friday's trading session, reaching their highest level since February 13. The surge came after the company announced that its key drug, Ryoncil, received a U.S. Medicare J-code, a development that significantly enhances the drug's reimbursement prospects and patient accessibility.

Ryoncil is Mesoblast's treatment for steroid-refractory acute graft versus host disease in pediatric patients, a condition that can occur after blood cell transplants. The drug represents a crucial part of Mesoblast's product portfolio, addressing a serious medical need in transplant recipients.

The U.S. Medicare J-code approval marks a significant milestone for Ryoncil, as it streamlines billing and payment processes for healthcare providers. This development is expected to facilitate broader patient access to the treatment and potentially boost Mesoblast's revenue streams. The market's enthusiastic response underscores the importance of this regulatory advancement, positioning Mesoblast for what could be its strongest week since mid-July.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1162680072"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1162680072\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1162680072?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-03 09:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162680072","market":"sg","top_or_hot":-1,"title":"Stock Track | Mesoblast Soars 16.93% as Key Drug Ryoncil Secures US Medicare Billing Approval","media":"Stock Track","content":"<p>Mesoblast Ltd (MSB.AU) shares skyrocketed 16.93% in Friday's trading session, reaching their highest level since February 13. The surge came after the company announced that its key drug, Ryoncil, received a U.S. Medicare J-code, a development that significantly enhances the drug's reimbursement prospects and patient accessibility.</p>\n\n<p>Ryoncil is Mesoblast's treatment for steroid-refractory acute graft versus host disease in pediatric patients, a condition that can occur after blood cell transplants. The drug represents a crucial part of Mesoblast's product portfolio, addressing a serious medical need in transplant recipients.</p>\n\n<p>The U.S. Medicare J-code approval marks a significant milestone for Ryoncil, as it streamlines billing and payment processes for healthcare providers. This development is expected to facilitate broader patient access to the treatment and potentially boost Mesoblast's revenue streams. The market's enthusiastic response underscores the importance of this regulatory advancement, positioning Mesoblast for what could be its strongest week since mid-July.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Mesoblast Soars 16.93% as Key Drug Ryoncil Secures US Medicare Billing Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Mesoblast Soars 16.93% as Key Drug Ryoncil Secures US Medicare Billing Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-10-03 09:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Mesoblast Ltd (MSB.AU) shares skyrocketed 16.93% in Friday's trading session, reaching their highest level since February 13. The surge came after the company announced that its key drug, Ryoncil, received a U.S. Medicare J-code, a development that significantly enhances the drug's reimbursement prospects and patient accessibility.</p>\n\n<p>Ryoncil is Mesoblast's treatment for steroid-refractory acute graft versus host disease in pediatric patients, a condition that can occur after blood cell transplants. The drug represents a crucial part of Mesoblast's product portfolio, addressing a serious medical need in transplant recipients.</p>\n\n<p>The U.S. Medicare J-code approval marks a significant milestone for Ryoncil, as it streamlines billing and payment processes for healthcare providers. This development is expected to facilitate broader patient access to the treatment and potentially boost Mesoblast's revenue streams. The market's enthusiastic response underscores the importance of this regulatory advancement, positioning Mesoblast for what could be its strongest week since mid-July.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MSB.AU","symbol_name":"MESOBLAST LTD","start_time":0,"source_url":"","article_id":"1162680072","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162680072","pubTimestamp":1759455617,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Mesoblast Ltd (MSB.AU) shares skyrocketed 16.93% in Friday's trading session, reaching their highest level since February 13. The surge came after the company announced that its key drug, Ryoncil,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MSB.AU":"MESOBLAST LTD"},"translate_title":"个股追踪|关键药物Ryoncil获美国医保计费批准Mesoblast飙升16.93%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MSB.AU":1},"content_text":"Mesoblast Ltd (MSB.AU) shares skyrocketed 16.93% in Friday's trading session, reaching their highest level since February 13. The surge came after the company announced that its key drug, Ryoncil, received a U.S. Medicare J-code, a development that significantly enhances the drug's reimbursement prospects and patient accessibility.\nRyoncil is Mesoblast's treatment for steroid-refractory acute graft versus host disease in pediatric patients, a condition that can occur after blood cell transplants. The drug represents a crucial part of Mesoblast's product portfolio, addressing a serious medical need in transplant recipients.\nThe U.S. Medicare J-code approval marks a significant milestone for Ryoncil, as it streamlines billing and payment processes for healthcare providers. This development is expected to facilitate broader patient access to the treatment and potentially boost Mesoblast's revenue streams. The market's enthusiastic response underscores the importance of this regulatory advancement, positioning Mesoblast for what could be its strongest week since mid-July.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}